四環醫藥(00460.HK)旗下北京渼顏空間生物醫藥獲主席車馮升入股 以擴大市場份額
格隆匯1月21日丨四環醫藥(00460.HK)發佈公吿,於2021年1月21日,認購人Euromax Holdings Limited、HoldCo(由公司執行董事兼主席車馮升醫生間接全資擁有)及目標公司北京渼顏空間生物醫藥有限公司(公司全資附屬公司)訂立認購協議,據此,認購人已有條件地同意認購而目標公司已有條件地同一銚行目標公司人民幣555.56萬元的註冊資本,代價為人民幣1350萬元。
目標公司為一家於2018年5月29日在中國成立的有限責任公司,主要從事銷售醫療美容產品(如肉毒桿菌毒素)。
董事會認為,認購事項產生的代價現金流入可加強目標公司的研究、投資、合併與收購能力及擴大市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.